Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by venture009on Jan 04, 2024 1:18pm
108 Views
Post# 35810865

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:black out is over, but where's the beef?

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:black out is over, but where's the beef?Azz34, sorry to disappoint you but I will not be going anywhere. I sold most of my holding after the reverse split at a considerable loss, but my wife and I retained 20,000 with the hope of recouping something if they are bought out. I suspect if there is a chance of a buyout, looking bleak at the moment, then the price will be between $20 and $30. My break even is just over $30 after 23 years.  After watching , and frankly hoping, this management would have learned something about what it takes to get across the finish line but they contiues to follow to same play book that they have followed for years with contiued decline in shareholder value. I will contiue to criticize this management as long as they keep doing the same thing. In fact I think they have gotten worse over the years Coffey clearly has no clue. He botched the breast cancer and now he is on the way to doing the same with panc. 
<< Previous
Bullboard Posts
Next >>